FDA raises safety, efficacy questions for FibroGen's anemia drug roxadustat with adcomm on the horizon
Ahead of Thursday’s meeting of the FDA’s Cardiovascular and Renal Drugs Advisory Committee, the agency is raising fresh doubts on whether FibroGen’s anemia drug roxadustat …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
